Kappa opioids and the modulation of pain

Psychopharmacology

Volumn 210, Issue 2, 2010, Pages 109-119

  Kivell, Bronwyn ^a   Prisinzano, Thomas E ^b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Dynorphin; Hallucinogen; Kappa opioid; Opioid; Pain; Salvia divinorum; Salvinorin a

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 3,4 DICHLORO N [1 ISOPROPYL 2 (1 PYRROLIDINYL)ETHYL] N METHYLBENZENEACETAMIDE; ACETAMIDE DERIVATIVE; ADL 100101; ASIMADOLINE; C 1977; CR 665; DEXTRO PHENYLALANINE DEXTRO PHENYLALANINE DEXTRO LEUCINE DEXTRO ORNITHINE MORPHOLINE AMIDE; DEXTRO PHENYLALANINE DEXTRO PHENYLALANINE DEXTRO NORLEUCINE DEXTRO ARGININE PICOLYL AMIDE; DITERPENE; DYNORPHIN; DYNORPHIN A; ETHYLKETAZOCINE; FE 20065; FE 200665; FE 200666; JNJ 38488502; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALORPHINE; NALOXONE; NORBINALTORPHIMINE; PENTAZOCINE; PLACEBO; SALVINORIN A; SK 9709; TETRAPEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2 AMINO N [2 (3 HYDROXY 1 PYRROLIDINYL) 1 PHENYLETHYL] N METHYLPHENYLACETAMIDE; ADL 10 0101; ANALGESIC AGENT; ENADOLINE; ICI 204488; MOM SAL B; N (3 METHYLFURFURYL)NORMETAZOCINE; N (TETRAHYDROFURFURYL)NORMETAZOCINE; U 504811; U 5048811;

ADJUVANT ARTHRITIS; ALLODYNIA; ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; CLINICAL TRIAL; COLON DILATATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; DYSPHORIA; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; INFLAMMATION; IRRITABLE COLON; MECHANORECEPTOR; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN; PATHOPHYSIOLOGY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SEDATION; SENSORY NERVE CELL; SENSORY STIMULATION; SIDE EFFECT; STIMULATION; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN; WRITHING TEST; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; COLITIS; DIARRHEA; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; NERVE COMPRESSION; NEUROMODULATION; SENSITIZATION; THERMAL STIMULATION;

ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MECHANORECEPTORS; NOCICEPTORS; PAIN; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 77953287151     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1819-6     Document Type: Review

References (140)

1. Ackley MA, Hurley RW, Virnich DE, Hammond DL (2001) A cellular mechanism for the antinociceptive effect of a kappa opioid receptor agonist. Pain 91:377-388
2. Aldrich JV, McLaughlin JP (2009) Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 11:312-322
3. Aldrich JV, Vigil-Cruz SC (2003) Narcotic analgesics. In: Abraham DA (ed) Burger's medicinal chemistry and drug discovery. Wiley, New York, pp 329-441
4. Alreja M, Mutalik P, Nayar U, Manchanda SK (1984) The formalin test: a tonic pain model in the primate. Pain 20:97-105
5. Andreev N, Urban L, Dray A (1994) Opioids suppress spontaneous activity of polymodal nociceptors in rat paw skin induced by ultraviolet irradiation. Neuroscience 58:793-798
6. Ansonoff MA, Zhang J, Czyzyk T, Rothman RB, Stewart J, Xu H, Zjwiony J, Siebert DJ, Yang F, Roth. BL, Pintar JE (2006) Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 318:641-648
7. Arendt-Nielsen L, Olesen AE, Staahl C, Menzaghi F, Kell S, Wong GY, Drewes AM (2009) Analgesic efficacy of peripheral kappaopioid receptor agonist CR665 compared, to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology 111:616-624
8. Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, Mauler F, Minck KO, Murray RD, Simon M et al (1994) A pharmacological profile of the novel, peripherallyselective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 113:1317-1327
9. Bender HM, Dasenbrock J (1998) Brain concentrations of asimadoline in mice: the influence of coadministration of various Pglycoprotein substrates. Int J Clin Pharmacol Ther 36:76-79
10. Bennett G, Xie Y (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107
11. Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO (1998) Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 76:317-325
12. Bileviciute-Ljungar I, Saxne T, Spetea M (2006) Anti-inflammatory effects of contralateral administration of the {kappa}-opioid agonist U-50, 488H in rats with, unilaterally induced adjuvant arthritis. Rheumatology 45:295-302
13. Binder W, Machelska H, Mousa S, Schmitt T, Riviere PJ, Junien JL, Stein C, Schafer M (2001) Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology 94:1034-1044
14. Bohn LM, Raehal KM (2006) Opioid receptor signaling: relevance for gastrointestinal therapy. Curr Opin Pharmacol 6:559-563
15. Burton MB, Gebhart GF (1995) Effects of intracolonic acetic acid, on responses to colorectal distension in the rat. Brain Res 672:77-82
16. Burton MB, Gebhart GF (1998) Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 285:707-715
17. Byers MR, Narhi MVO (1999) Dental injury models: experimental tools for understanding neuroinflammatory interactions and polymodal nociceptor functions. Crit Rev Oral Biol Med 10:4-39
18. Camilleri M (2008) Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 20:971-979
19. Carlton S, Coggeshall RE (1998) Nociceptive integration: does it have a peripheral component? Pain Forum 7:71-78
20. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D (1999) A. capsaicin-receptor homologue with a high threshold for noxious heat. Nature 398:436-441
21. Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE (2005) Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2, 3-dihydrobenzofuran-based constraints. Bioorg Med Chem Lett 15:5114-5119
22. Chu GH, Gu M, Cassel JA, Belanger S, Graczyk TM, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE (2007) Novel malonamide derivatives as potent kappa opioid receptor agonists. Bioorg Med Chem Lett 17:1951-1955
23. Chu GH, Gu M, Cassel JA, Belanger S, Stabley GJ, DeHaven RN, Conway-James N, Koblish M, Little PJ, DeHaven-Hudkins DL, Dolle RE (2006) Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists. Bioorg Med Chem Lett 16:645-648
24. Corbett AD, Henderson G, McKnight AT, Paterson SJ (2006) 75 years of opioid, research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147(Suppl 1):S153-S162
25. Craft RM, Carlisi VJ, Mattia A, Herman RM, Porreca F (1993) Behavioral characterization of the excitatory and desensitizing effects of intravesical capsaicin and resiniferatoxin in the rat. Pain 55:205-215
26. Craig A (1991) Spinal distribution of ascending lamina I axons anterogradely labeled with Phaseolus vulgaris leucoagglutinin (PHA-L) in the cat. J Comp Neurol 313:377-393
27. Danzebrink R, Green S, Gebhart GF (1995) Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain 63:39-47
28. DeHaven-Hudkins DL, Dolle RE (2004) Peripherally restricted opioid, agonists as novel analgesic agents. Curr Pharm Des 10:743-757
29. Delgado-Aros S, Chiai HJ, Camilleri M, Szarka LA, Weber FT, Jacob J, Ferber I, McKinzie S, Burton DD, Zinsmeister AR (2003) Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 284:G558-G566
30. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad. Sci USA 85:5274-5278
31. Diop L, Rivière P, Pascaud X, Junien J (1994) Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex in rat. Eur J Pharmacol 271:65-71
32. Dubinsky B, Gebre-Mariam S, Capetola R, Rosenthale M (1987) The antialgesic drugs: human therapeutic correlates of their potency in laboratory animal models of hyperalgesia. Agents Actions 20:50-60
33. Dubner R, Ren K (1999) Endogenous mechanisms of sensory modulation. Pain Suppl 6:S45-S53
34. Dubuisson D, Dennis SG (1977) The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4:161-174
35. Eddy NB (1948) Pharmacology of metopon and other new analgesic opium derivatives. Ann N Y Acad. Sci 51:51-58
36. Eisenach JC, Carpenter R, Curry R (2003) Analgesia from, a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 101:89-95
37. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J (2004) Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 112:83-93
38. Field. MJ, Carnell AJ, Gonzalez MI, McCleary S, Oles RJ, Smith R, Hughes J, Singh L (1999) Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain 80:383-389
39. Floyd. BN, Camilleri M, Busciglio I, Sweetser S, Burton D, Wong GY, Kell S, Khanna S, Hwang S, Zinsmeister AR (2009) Effect of a. kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers. Neurogastroenterol Motil 21:281-290
40. Freye E, Hartung E, Schenk GK (1983) Bremazocine: an opiate that induces sedation and analgesia without respiratory depression. Anesth. Analg 62:483-488
41. Gebhart GF (1996) Visceral polymodal receptors. Prog Brain Res 113:101-112
42. Gebhart GF, Su X, Joshi S, Ozaki N, Sengupta JN (2000) Peripheral opioid modulation of visceral pain. Ann N Y Acad Sci 909:41-50
43. Gebhart G (1995) Progress in pain research and management visceral pain. International Association for the Study of Pain, International Association for the Study of Pain
44. George SR, Zastawny RL, Brionesurbina R, Cheng R, Nguyen T, Heiber M, Kouvelas A, Chan AS, O'Dowd BF (1994) Distinct Distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem Biophys Res Commun 205:1438-1444
45. Giordano J (2005) the neurobiology of nociceptive and antinociceptive systems. Pain Physician 8:227-290
46. Gottschlich R, Barber A, Bartoszyk GD, Seyfried CA (1995) The peripherally acting kappa-opiate agonist EMD 61753 and analogues: opioid activity versus peripheral selectivity. Drugs Exp Clin Res 21:171-174
47. Gruber CM Jr, Lee KS, Gruber CM (1950) A comparison of the actions of meperidine, nu-1196, methadone, morphine, nu-2206, and metopon upon the intestine and uterus. J Pharmacol Exp Ther 99:317-324
48. Gutstein HB, Akil H (2001) Opioid. Analgesics. In: Goodman LS, Hardman JG, Limbird LE, Oilman AG (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGrawHill, New York, pp 569-619
49. Harada T, Takahashi H, Kaya H, Inoki R (1979) A test for analgesics as an indicator of locomotor activity in writhing mice. Arch Int Pharmacodyn Ther 242:273-284
50. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988) A new and sensitive method, for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88
51. Harvey V, Dickenson A (2009) Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57B1/6 mice. Molecular Pain 5:18
52. Herrero J, Headley PM (1991) The effects of sham and full spinalization on the systemic potency of mu- and kappa-opioids on spinal, nociceptive reflexes in rats. Br J Pharmacol 104:166-170
53. Hirarnatsu M, Inoue M, Ambo A, Saski Y, Kameyama T (2001) Longlasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice. Br J Pharmacol 132:1948-1956
54. Hooker JM, Munro TA, Beguin C, Alexoff D, Shea C, Xu Y, Cohen BM (2009) Salvinorin A and derivatives: protection from metabolism, does not prolong short-term, whole-brain residence. Neuropharmacology 57:386-391
55. Horan PJ, Porreca F (1993) Lack of cross-tolerance between U69, 593 and bremazocine suggests kappa-opioid receptor multiplicity in mice. Eur J Pharmacol 239:93-98
56. Hunskaar S, Hole K (1987) The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 30:103-114
57. Iadarola M, Brady L, Draisci G, Dubner R (1988) Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. Pain 35:312-326
58. John TF, French LG, Erlichman JS (2006) The antinociceptive effect of Salvinorin A in mice. Eur J Pharmacol 545:129-133
59. Kandel E, Schwartz J, Jessell T (2000) Principles of Neural Science, 4th edn. McGraw-Hill, McGraw-Hill
60. Keats AS, Beecher HK (1952) Analgesic potency and side action liability in man of heptazone, WIN 1161-2, 6-methyl dihydromorphine, metopon, levo-isomethadone and pentobarbital sodium, as a further effort to refine methods of evaluation of analgesic drugs. J Pharmacol Exp Ther 105:109-129
61. Keïta H, Kayser V, Guilbaud G (1995) Antinociceptive effect of a kappa-opioid receptor agonist that minimally crosses the bloodbrain barrier (ICI 204448) in a rat model of mononeuropathy. Eur J Pharmacol 277:275-280
62. Kim S, Chung J (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355-363
63. Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968
64. Larsson M, Arvidsson S, Ekman C, Bayati A (2003) A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists. Neurogastroenterol Motil 15:371-381
65. Le Bars D, Gozariu M, Cadden SW (2001) animal models of nociception. Pharmacol Rev 53:597-652
66. Le Bourdonnec B, Ajello CW, Seida PR, Susnow RG, Cassei JA, Belanger S, Stabley GJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE (2005) Arylacetamide kappa opioid, receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem. Lett 15:2647-2652
67. Machelska H, Pfluger M, Weber W, Piranvisseh-Volk M, Daubert JD, Dehaven R, Stein C (1999) Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 290:354-361
68. Mansour A, Fox C, Burke S, Meng F, Thompson R, Akil H, Watson S (1994) Mu, delta, and kappa opioid, receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350:412-438
69. Martin M, Matifas A, Maldonado R, Kieffer B (2003a) Acute antinocioceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. Eur J NeuroSci 17:701-708
70. Martin W, Stewart L, Tarpley J (2003b) Animal models of neuropathic pain. Methods Mol Med 84:233-242
71. Martin WR, Fraser HF, Gorodetzky CW, Rosenberg DE (1965) Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl- 2′-hydroxy-5, 9-dimethyl-6, 7-benzomorphan (cyclazocine, WIN-20, 740, ARC II-c-3). J Pharmacol Exp Ther 150:426-436
72. Martínez-Gómez M, Cruz Y, Salas M, Hudson R, Pacheco P (1994) Assessing pain threshold in the rat: changes with estrus and time of day. Physiol Behav 55:651-657
73. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ (2006) Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav 83:109-113
74. McNally GP, Akil H (2002) Opioid peptides and then- receptors: overview and function in pain modulation. In: Davis KL (ed) Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, pp 35-46
75. Meiler ST, Gebhart GF (1997) Intraplantar zymosan as a reliable, quantifiable model of thermal and mechanical hyperalgesia in the rat. Eur J Pain 1:43-52
76. Miampamba M, Chéry-Croze S, Gorry F, Berger F, Chayvialle JA (1994) Inflammation of the colonic wall induced by formalin as a model of acute visceral pain. Pain 57:227-234
77. Millan MJ (1990) [kappa]-Opioid receptors and analgesia. Trends Pharmacol Sci 11:70-76
78. Millan MJ, Czlonkowski A, Monis B, Stein C, Arendt R, Huber A, Holit V, Herz A (1988) Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain 35:299-312
79. Mochizucki D (2004) Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp 19: S15-S19
80. Ness T (1999) Models of visceral nociception. ILAR J 40:119-128
81. Obara I, Parkitna JR, Korostynski M, Makuch W, Kaminska D, Przewlocka B, Przewlocki R (2009) Local peripheral opioid, effects and expression of opioid genes in the spinal cord, and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141:283-291
82. Ossipov MH, Kovelowski CJ, Wheeler-Aceto H, Cowan A, Hunter JC, Lai J, Malan TP Jr, Porreca F (1996) Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone. J Pharmacol Exp Ther 277:784-788
83. Panneton W (1991) Primary afferent projections from the upper respiratory tract in the muskrat. J Comp Neurol. 308:51-65
84. Peckys D, Landwehrmeyer GB (1999) Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 88:1093-1135
85. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776
86. Porreca F, Burks TF (1983) The spinal cord as a site of opioid effects on gastrointestinal transit in the mouse. J Pharmacol Exp Ther 227:22-27
87. Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid, receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230:341-348
88. Porreca F, Mosberg HI, Omnaas JR, Burks TF, Cowan A (1987) Supraspinal and spinal potency of selective opioid agonists in the mouse writhing test. J Pharmacol Exp Ther 240:890-894
89. Prentice T, Joynes RL, Meagher MW, Grau JW (1996) Impact of shock on pain reactivity: III. The magnitude of hypoalgesia observed, depends on test location. Behav Neurosci 110:528-541
90. Prisinzano TE, Gebhart GF (2007) Pain overview. In: Taylor JB, Triggle DJ (eds) Comprehensive medicinal chemistry. Elsevier, New York, pp 321-326
91. Prisinzano TE, Rothman RB (2008) Salvinorin A analogs as probes in opioid pharmacology. Chem Rev 108:1732-1743
92. Przewlocki R, Przewlocka B (2001) Opioids in chronic pain. Eur J Pharmacol 429:79-91
93. Rau KK, Caudle RM, Cooper BY, Johnson RD (2005) Diverse immunocytochemical expression of opioid receptors in electrophysiologically defined cells of rat dorsal root ganglia. J Chem Neuroanat 29:255-264
94. Ravert H, Bencherif B, Madar I, Frost J (2004) PET imaging of opioid receptors in pain: progress and new directions. Curr Pharm Des 10:759-768
95. Rice ASC, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, Mogil JS, Stöhr T (2008) Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139:243-247
96. Rice KC (2003) Analgesic research at the National Institutes of Health: State of the Art 1930s to the Present. In: Meldrum ML (ed) Opioids and pain relief: a historical perspective, progress in pain research and management. IASP, Seattle, pp 57-83
97. Riedel W, Neeck G (2001) Nociception, pain, and antinociception: current concepts. Z Rheumatol 60:404-415
98. Rimoy GH, Wright DM, Bhaskar NK, Rubin PC (1994) The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur J Clin Pharmacol 46:203-207
99. Rivière P (2004) Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 141:1331-1334
100. Schepers RJ, Mahoney JL, Gehrke BJ, Shippenberg TS (2008) Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral, inflammation. Pain 138:423-439
101. Sengupta J, Snider A, Su X, Gebhart GF (1999) Effects of kappa opioids in the inflamed rat colon. Pain 79:175-185
102. Shannon HE, Eberle EL, Mitch CH, McKinzie DL, Statnick MA (2007) Effects of kappa opioid receptor agonists on attention as assessed, by a 5-choice serial reaction time task in rats. Neuropharmacology 53:930-941
103. Shippenberg TS, Stein C, Huber A, Millan MJ, Herz A (1988) Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists. Pain 35:179-186
104. Siegmund E, Cadmus R, Lu G (1957) A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med 95:729-731
105. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50, 488H and attenuates morphine withdrawal. EMBO J 17:886-897
106. Small L, Fitch HM, Smith WE (1936) The addition of organomagnesium halides to pseudocodeine types. II. Preparation of nuclear alkylated morphine derivatives. J Am Chem Soc 58:1457-1463
107. Spanagel R, Herz A, Shippenberg T (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad. Sci USA 89:2046-2050
108. Stein C (1991) Peripheral analgesic actions of opioids. J Pain Symptom Manage 6:119-124
109. Stein C (1993) Peripheral mechanisms of opioid analgesia. Anesth Analg 76:182-191
110. Stein C, Lang LJ (2009) Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 9:3-8
111. Stein C, Cabot PJ, Schafer M (1999) Peripheral opioid analgesia: mechanisms and clinical implications. In: Stein C (ed.) Opioids in pain control: basic and clinical aspects. Cambridge University Press, Cambridge, pp 96-108
112. Stein C, Gramsch C, Herz A (1990) Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 10:1292-1298
113. Stein C, Millan MJ, Shippenberg TS, Herz A (1988) Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci Lett 84:225-228
114. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A (1989) Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 248:1269-1275
115. Su X, Sengupta .TN, Gebhart GF (1997) Effects of kappa opioid receptor-selective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol 78:1003-1012
116. Su X, Julia V, Gebhart GF (2000) Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 83:963-970
117. Sufka K, Watson G, Nothdurft R, Mogil J (1998) Scoring the mouse formalin test: validation study. Eur J Fain 2:351-358
118. Takasaki I, Andoh T, Shiraki K, Kuraishi Y (2000) Allodynia and hyperalgesia induced by herpes simplex virus type-1 infection in mice. Pain 86:95-101
119. Teksin ZS, Lee IJ, Nemieboka NN, Othman AA, Upreti VV, Hassan HE, Syed SS, Prisinzano TE, Eddington ND (2009) Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72:471-477
120. Tempel A, Zukin RS (1987) Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc Natl Acad Sci USA 84:4308-4312
121. Tjølsen A, Rosland J, Berge O, Hole K (1991) The increasingtemperature hot-plate test: an improved test of nociception in mice and rats. J Pharmacol Methods 25:241-250
122. Tuthill PA, Seida PR, Barker W, Cassel JA, Belanger S, DeHaven RN, Koblish M, Gottshall SL, Little PJ, DeHaven-Hudkins DL, Dolle RE (2004) Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists. Bioorg Med Chem Lett 14:5693-5697
123. Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69:503-512
124. Unterwald E, Sasson S, Kornetsky C (1987) Evaluation of the supraspinal analgesic activity and abuse liability of ethylketocyclazocine. Eur J Pharmacol 133:275-281
125. Vander Wende C, Margolin S (1956) Analgesic tests based upon experimentally induced acute abdominal, pain in rats. Fed Proc 15:494
126. Vanderah TW (2010) Delta and kappa opioid, receptors as suitable drug targets for pain. Clin J Pain 26(Suppl 10):S10-S15
127. Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean. R, Schteingart C, Junien JL, Trojnar J, Riviere PJ (2008) Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol 583:62-72
128. Walker J (2003) Anti-inflammatory effects of opioids. Adv Exp Med Biol 521:148-160
129. Walker J, Catheline G, Guillbaud G, Kayser V (1999) Lack, of crosstolerance between the antinociceptive effects of systemic morphine and asmadoline, a peripherially-selective kappa-opioid agonist, in CCI-neuropathic rats. Pain 83:509-516
130. Walker JS, Scott C, Bush KA, Kirkham BW (2000) Effects of the peripherally selective [kappa] -opioid asimadoline, on substance P and CGRP mRNA expression in chronic arthritis of the rat. Neuropeptides 34:193-202
131. Walsh SL, Strata EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology 157:151-162
132. Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U, Hruby VJ, Malan TP Jr, Lai J, Porreca F (2001) Pronociceptive actions of dynorphin maintain chronic pain. J Neuroscience 21(5): 1779-1786
133. Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, LiuChen LY (2008) 2-Methoxymethyl-salvtaorta B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 324:1073-1083
134. Wesselmann U, Lai J (1997) Mechanisms of referred visceral pain: uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin. Pain 73:309-317
135. Willis W Jr (1985) The pain system. The neural basis of nocioceptive transmission in the mammalian nervous system. Pain Headache 8:1-346
136. Willis WD, Westlund KN (1997) Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 14:2-31
137. Wilson JL, Carmody JJ, Walker JS (2000) The importance of the hypothalamo-hypophyseal-adrenal axis to the antiinflammatory actions of the kappa-opioid agonist PNU-50, 488H in rats with, adjuvant arthritis. J Pharmacol Exp Ther 294:1131-1136
138. Xu M, Petraschka M, McLaughlin JP, Westenbroek RE, Caron MG, Lefkowitz RJ, Czyzyk. TA, Pintar JE, Chavkin C (2004) Neuropathic pain activates the endogenous kappa opioid, system in mouse spinal cord and induces opioid receptor tolerance. J Neuroscience 24:4576-4584
139. Yoburn B, Morales R, Kelly D, Inturrisi C (1984) Constraints on the tailflick assay: morphine analgesia and tolerance are dependent upon locus of tail stimulation. Life Sci 34:1755-1762
140. Zhou L, Zhang Q, Stein C, Schäfer M (1998) Contribution of opioid, receptors on primary afferent versus sympathetic neurons to peripheral opioid, analgesia. J Pharmacol Exp Ther 286:1000-1006